This document discusses chemical kinetics and stability testing of pharmaceutical products. It covers the basic requirements of drugs including efficacy, safety and stability. The purpose of stability testing is to provide evidence on how drug quality varies over time under different environmental factors like temperature, humidity and light, and to establish a shelf life and recommended storage conditions. The document discusses the rates, orders and molecularity of chemical reactions, including zero-order, first-order and second-order reactions. It also covers rate constants, half-lives, shelf lives and units of basic rate constants. Accelerated stability testing is used to increase reaction rates by exaggerated storage conditions to assess longer-term effects.
Expt. 10 effect of spasmogens and spasmolytics using rabbit jejunumVISHALJADHAV100
Overview of Discussion
Objective
Principle
Requirements
Experimental specifications (conditions)
Drugs and solutions used in rabbit intestine experiment
Preparation of Tyrode solution (PSS)
Procedure
Kymograph recording of contractions
Observation table
Result and interpretation
Expt. 10 effect of spasmogens and spasmolytics using rabbit jejunumVISHALJADHAV100
Overview of Discussion
Objective
Principle
Requirements
Experimental specifications (conditions)
Drugs and solutions used in rabbit intestine experiment
Preparation of Tyrode solution (PSS)
Procedure
Kymograph recording of contractions
Observation table
Result and interpretation
Expt. 6 Bioassay of histamine using guinea pig ileum by matching methodVISHALJADHAV100
Objective
Principle
Requirements
Experimental specifications (conditions)
Preparation of histamine standard solution
Preparation of Tyrode solution (PSS)
Procedure
Kymograph recording of contractions
Observation table
Calculation
Result and interpretation
Expt. 6 Study of effect of drugs on gastrointestinal motilityVISHALJADHAV100
Objective
Principle
Requirements
Preparation of Tyrode solution
Procedure
Kymograph recording of contractions
Observation table
Result and Interpretation
Tetracyclines,Biological sources,History,Sturctures,SAR,Mechanism of action,Spectrum of activity,Important structural units and the three acidity constants in the tetracycline molucule,amphoteric nature,epimerisation, chelation with metals,toxicity and uses.
Expt. 6 Bioassay of histamine using guinea pig ileum by matching methodVISHALJADHAV100
Objective
Principle
Requirements
Experimental specifications (conditions)
Preparation of histamine standard solution
Preparation of Tyrode solution (PSS)
Procedure
Kymograph recording of contractions
Observation table
Calculation
Result and interpretation
Expt. 6 Study of effect of drugs on gastrointestinal motilityVISHALJADHAV100
Objective
Principle
Requirements
Preparation of Tyrode solution
Procedure
Kymograph recording of contractions
Observation table
Result and Interpretation
Tetracyclines,Biological sources,History,Sturctures,SAR,Mechanism of action,Spectrum of activity,Important structural units and the three acidity constants in the tetracycline molucule,amphoteric nature,epimerisation, chelation with metals,toxicity and uses.
Chemical kinetics, also known as reaction kinetics, is the branch of physical chemistry that is concerned with understanding the rates of chemical reactions. It is to be contrasted with thermodynamics, which deals with the direction in which a process occurs but in itself tells nothing about its rate.
CHAPTER 1 SEMESTER V PREVENTIVE-PEDIATRICS.pdfSachin Sharma
This content provides an overview of preventive pediatrics. It defines preventive pediatrics as preventing disease and promoting children's physical, mental, and social well-being to achieve positive health. It discusses antenatal, postnatal, and social preventive pediatrics. It also covers various child health programs like immunization, breastfeeding, ICDS, and the roles of organizations like WHO, UNICEF, and nurses in preventive pediatrics.
India Clinical Trials Market: Industry Size and Growth Trends [2030] Analyzed...Kumar Satyam
According to TechSci Research report, "India Clinical Trials Market- By Region, Competition, Forecast & Opportunities, 2030F," the India Clinical Trials Market was valued at USD 2.05 billion in 2024 and is projected to grow at a compound annual growth rate (CAGR) of 8.64% through 2030. The market is driven by a variety of factors, making India an attractive destination for pharmaceutical companies and researchers. India's vast and diverse patient population, cost-effective operational environment, and a large pool of skilled medical professionals contribute significantly to the market's growth. Additionally, increasing government support in streamlining regulations and the growing prevalence of lifestyle diseases further propel the clinical trials market.
Growing Prevalence of Lifestyle Diseases
The rising incidence of lifestyle diseases such as diabetes, cardiovascular diseases, and cancer is a major trend driving the clinical trials market in India. These conditions necessitate the development and testing of new treatment methods, creating a robust demand for clinical trials. The increasing burden of these diseases highlights the need for innovative therapies and underscores the importance of India as a key player in global clinical research.
The dimensions of healthcare quality refer to various attributes or aspects that define the standard of healthcare services. These dimensions are used to evaluate, measure, and improve the quality of care provided to patients. A comprehensive understanding of these dimensions ensures that healthcare systems can address various aspects of patient care effectively and holistically. Dimensions of Healthcare Quality and Performance of care include the following; Appropriateness, Availability, Competence, Continuity, Effectiveness, Efficiency, Efficacy, Prevention, Respect and Care, Safety as well as Timeliness.
ICH Guidelines for Pharmacovigilance.pdfNEHA GUPTA
The "ICH Guidelines for Pharmacovigilance" PDF provides a comprehensive overview of the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) guidelines related to pharmacovigilance. These guidelines aim to ensure that drugs are safe and effective for patients by monitoring and assessing adverse effects, ensuring proper reporting systems, and improving risk management practices. The document is essential for professionals in the pharmaceutical industry, regulatory authorities, and healthcare providers, offering detailed procedures and standards for pharmacovigilance activities to enhance drug safety and protect public health.
Telehealth Psychology Building Trust with Clients.pptxThe Harvest Clinic
Telehealth psychology is a digital approach that offers psychological services and mental health care to clients remotely, using technologies like video conferencing, phone calls, text messaging, and mobile apps for communication.
Antibiotic Stewardship by Anushri Srivastava.pptxAnushriSrivastav
Stewardship is the act of taking good care of something.
Antimicrobial stewardship is a coordinated program that promotes the appropriate use of antimicrobials (including antibiotics), improves patient outcomes, reduces microbial resistance, and decreases the spread of infections caused by multidrug-resistant organisms.
WHO launched the Global Antimicrobial Resistance and Use Surveillance System (GLASS) in 2015 to fill knowledge gaps and inform strategies at all levels.
ACCORDING TO apic.org,
Antimicrobial stewardship is a coordinated program that promotes the appropriate use of antimicrobials (including antibiotics), improves patient outcomes, reduces microbial resistance, and decreases the spread of infections caused by multidrug-resistant organisms.
ACCORDING TO pewtrusts.org,
Antibiotic stewardship refers to efforts in doctors’ offices, hospitals, long term care facilities, and other health care settings to ensure that antibiotics are used only when necessary and appropriate
According to WHO,
Antimicrobial stewardship is a systematic approach to educate and support health care professionals to follow evidence-based guidelines for prescribing and administering antimicrobials
In 1996, John McGowan and Dale Gerding first applied the term antimicrobial stewardship, where they suggested a causal association between antimicrobial agent use and resistance. They also focused on the urgency of large-scale controlled trials of antimicrobial-use regulation employing sophisticated epidemiologic methods, molecular typing, and precise resistance mechanism analysis.
Antimicrobial Stewardship(AMS) refers to the optimal selection, dosing, and duration of antimicrobial treatment resulting in the best clinical outcome with minimal side effects to the patients and minimal impact on subsequent resistance.
According to the 2019 report, in the US, more than 2.8 million antibiotic-resistant infections occur each year, and more than 35000 people die. In addition to this, it also mentioned that 223,900 cases of Clostridoides difficile occurred in 2017, of which 12800 people died. The report did not include viruses or parasites
VISION
Being proactive
Supporting optimal animal and human health
Exploring ways to reduce overall use of antimicrobials
Using the drugs that prevent and treat disease by killing microscopic organisms in a responsible way
GOAL
to prevent the generation and spread of antimicrobial resistance (AMR). Doing so will preserve the effectiveness of these drugs in animals and humans for years to come.
being to preserve human and animal health and the effectiveness of antimicrobial medications.
to implement a multidisciplinary approach in assembling a stewardship team to include an infectious disease physician, a clinical pharmacist with infectious diseases training, infection preventionist, and a close collaboration with the staff in the clinical microbiology laboratory
to prevent antimicrobial overuse, misuse and abuse.
to minimize the developme
CHAPTER 1 SEMESTER V - ROLE OF PEADIATRIC NURSE.pdfSachin Sharma
Pediatric nurses play a vital role in the health and well-being of children. Their responsibilities are wide-ranging, and their objectives can be categorized into several key areas:
1. Direct Patient Care:
Objective: Provide comprehensive and compassionate care to infants, children, and adolescents in various healthcare settings (hospitals, clinics, etc.).
This includes tasks like:
Monitoring vital signs and physical condition.
Administering medications and treatments.
Performing procedures as directed by doctors.
Assisting with daily living activities (bathing, feeding).
Providing emotional support and pain management.
2. Health Promotion and Education:
Objective: Promote healthy behaviors and educate children, families, and communities about preventive healthcare.
This includes tasks like:
Administering vaccinations.
Providing education on nutrition, hygiene, and development.
Offering breastfeeding and childbirth support.
Counseling families on safety and injury prevention.
3. Collaboration and Advocacy:
Objective: Collaborate effectively with doctors, social workers, therapists, and other healthcare professionals to ensure coordinated care for children.
Objective: Advocate for the rights and best interests of their patients, especially when children cannot speak for themselves.
This includes tasks like:
Communicating effectively with healthcare teams.
Identifying and addressing potential risks to child welfare.
Educating families about their child's condition and treatment options.
4. Professional Development and Research:
Objective: Stay up-to-date on the latest advancements in pediatric healthcare through continuing education and research.
Objective: Contribute to improving the quality of care for children by participating in research initiatives.
This includes tasks like:
Attending workshops and conferences on pediatric nursing.
Participating in clinical trials related to child health.
Implementing evidence-based practices into their daily routines.
By fulfilling these objectives, pediatric nurses play a crucial role in ensuring the optimal health and well-being of children throughout all stages of their development.
R3 Stem Cells and Kidney Repair A New Horizon in Nephrology.pptxR3 Stem Cell
R3 Stem Cells and Kidney Repair: A New Horizon in Nephrology" explores groundbreaking advancements in the use of R3 stem cells for kidney disease treatment. This insightful piece delves into the potential of these cells to regenerate damaged kidney tissue, offering new hope for patients and reshaping the future of nephrology.
2. Introduction
Basic requirements of pharmaceutical products
• Efficacy: Optimum therapeutic level for specified
period of time.
• Safety: Minimum or no side effects.
• Stability: The products should retain their
properties during storage.
Physical Chemical
This should guarantee the efficacy and safety
3. • to provide evidence on how the quality of a
drug substance or drug product varies with
time under the influence of a variety of
environmental factors, such as temperature,
humidity, and light,
• and to establish a shelf life for the drug
product and recommended storage
conditions.
The purpose of stability testing is:
4. Chemical reaction rate
The study of rate of chemical degradation in
which the rate is influences by solvent ,
pressure ,and temperature of the product
and reactants
Reaction order are generally classified into :
•Zero order reaction
•First order reaction
•Second order reaction
•Third order reaction
•Pseudo first order reaction
5. Rates, Order, and Molecularity of Reactions
• The rate, velocity, or speed of a drug
degradation reaction is given by the expression
dc/dt,
• where dc is the increase or decrease of
concentration over an infinitesimal time
interval dt.
Zero 1st 2nd
• The order of the reaction is the manner by which
the concentration affects the rate of the reaction.
6. Rate Constants, Half-Life, Shelf Life, and
Apparent or Pseudo-order
• Specific Rate Constant:
• The Rate constant, k,
• Any change in the conditions of the reaction, for
example, in temperature or solvent, or a slight
change in one of the reacting species, will lead
to a rate law having a different value for the
specific rate constant.
7. • The half-life is the time required for one-half of
the material to disappear; it is the time at
which A (amount of the drug ) has decreased to
½ A°. initial concentration
• The shelf life is the time required for 10% of the
material to disappear; it is the time at
which A has decreased to 90% of its original
concentration (i.e., 0.9 A°. ).
9. zero-order reaction
In this type of reaction the rate of the reaction is independent of the
concentration of reactants , the rate of reaction expressed by :
• At or ct = remaining concentration of reactants
• k= constant reaction rate
• t= time
• A0 or C0= initial concentration of reactants
• t1/2 = half life
•Example :
Most of photochemical degradations are classified as zero order kinetic
Rate of reaction is constant
10. • The initial concentration corresponding to A0 is
ordinarily written as a and the concentration
remaining at time t as c.
• When this linear equation is plotted with c on
the vertical axis against t on the horizontal axis,
the slope of the line is equal to -k0.
slope Intercept
Intercept
11. zero-order reaction
• Because the half-life is the time required
for one-half of the material to disappear,
then:
•
• The shelf life is ( 0.1A°./ K° ).
t ½= Ao/ 2Ko
12. • Example:
• A prescription for a liquid aspirin preparation is
called for. It is to contain 325 mg/5 mL or
6.5 g/100 mL. Determine the shelf life a liquid
aspirin preparation, assuming that the at 25°C
zero-order reaction
13. first-order reaction
• When the rate of the reaction is proportional
to the first power of concentration of the
reactant
• Log Ct = Log C0 – Kt/ 2.303
• K = 2.203/t X Log C0 / Ct
• t1/2 = 0.693 /K
• Ct = concentration remaining at time t
• C0 = initial concentration
• K= reaction rate constant
• t1/2 = half life
14. • to obtain an average k for the reaction is to plot
the logarithm of the concentration against the
time.
• The linear expression in equation (14-13) shows
that the slope of the line is -k/2.303, from which
the rate constant is obtained.
• If a straight line is obtained, it indicates that the
reaction is first order.
17. • A solution of a drug contained 500 units/mL
when prepared. It was analyzed after 40 days
and was found to contain 300 units/mL.
• Assuming the decomposition is first order, at
what time will the drug have decomposed to
one-half of its original concentration?
18. • K = 2.203/t X Log C0 / Ct
• K = 2.203/ 40 day X Log 500 / 300
= 0.013 day -1
• t1/2 = 0.693 /K
= 0.693/ 0.013
= 54.2 day
day -1
19. • K = 2.203/t X Log C0 / Ct
• K = 2.203/ 57600 sec X Log 500 / 300
= 1.48 x10 -7
• t1/2 = 0.693 /K
= 0.693/ 1.48 x10 -7
= 468 x10 4
= 54.2 day
sec -1
sec
sec -1
20. • The time and amount of decomposition of
glucose at 40 °C in an aqueous solution of 0.35
N HCl was found to be: (Table)
• What is the order, half life, reaction rate
constant, initial concentration of glucose
• What is the remaining concentration after
16 hours.
• How long does it take for decomposition of 0.4 M
of glucose.
26. • the order ….. First order
• reaction rate constant = slope y2-y1 = - 001
x2-x1
• K = - ( - 0.01x 2.303 ) = 0.023 hr-1
• initial concentration of glucose = anti log -0.25
= 0.562 M
• half life …… t ½= 0.693/ K = 30.1 hr
• What is the remaining concentration after 16 hours.
Log ct = log 0.562 – 0.023 x 16 / 2.303 = - 0.41
ct = 0.389 M remaining concentration after 16 hours
• How long does it take for decomposition of 0.4 M of glucose.
Log 0.4 = log 0.562 – 0.023 x t /2.303
t= 14.8 hr
27. Home work
• 1) The half-life of Zn-71 is 2.4 minutes. If one had 100.0 g at the
beginning, how many grams would be left after 7.2 minutes has elapsed?
Answer 12.5
• 2) A solution of a drug contained 500 units/mL when prepared. It was
analyzed after 40 days and was found to contain 300 units/mL.
Assuming the decomposition is first order, at what time will the drug
have decomposed to one-half of its original concentration?
Answer 54.25 day
• 3) A solution of a drug contained 100 mg when prepared. How much of
the drug will remain after 2 days if the drug have decomposed to one-
half of its original concentration within 10 days ?Assuming the
decomposition is zero order …………Answer 90 mol/L
• 4) How long will it take for a 40.0 gram sample of I-131 (half-life = 8.040
days) to decay to 1/100 its original mass? …………Answer 53.5 days
28. • 1) The half-life of Zn-71 is 2.4 minutes. If one had
100.0 g at the beginning, how many grams would be
left after 7.2 minutes has elapsed?
• t1/2 = 0.693 /K
• K= 0.29 minutes-1
• Log Ct = Log C0 – Kt/ 2.303
• Log Ct = Log 100 – 0.3x 7.2/ 2.303 =1.06
• Ct= 12.5 g
29. • 2) A solution of a drug contained 500 units/mL when
prepared. It was analyzed after 40 days and was found
to contain 300 units/mL.
• Assuming the decomposition is first order, at what
time will the drug have decomposed to one-half of
its original concentration?
•
• Log Ct = Log C0 – Kt/ 2.303
• Log300 = Log 500 – K x40 days / 2.303
• 2.477=2.699- K 17.4
• K= 0.013 Sec-1
• t1/2 = 0.693 /K = 0.693/ 0.011 = 54.25 day
30. • 3) A solution of a drug contained 100 mg when prepared.
How much of the drug will remain after 2 days if the drug
have decomposed to one-half of its original
concentration within 10 days ?Assuming the
decomposition is zero order
• t1/2 = C0/ 2 K°
• 10 days = 100 mg / 2 K°
• K° = 100/ 2x10 = 5 mole /L.day
• Ct= C° - t K°
• Ct= 100 mg- 2days x 5 = 90 mole /L
C0
t 1/2
31. • 4) How long will it take for a 40.0 gram sample of
I-131 (half-life = 8.040 days) to decay to 1/100
its original mass?
• t1/2 = 0.693/ k
• K = 0.0862 day -1
• Log Ct = Log C0 – Kt/ 2.303
• Log 0.4 = log 40 – 0.086 t / 2.303
• t= 53.5 days
32. • A number of factors other than concentration
may affect the Chemical reaction velocity:
• temperature,
• solvents,
• catalysts,
• light.
The effect of various factors on drug
degradation :
33. Temperature Effects
Collision Theory
• Reaction rates are expected to be proportional to the
number of collisions per unit time.
• Because the number of collisions increases as the
temperature increases, the reaction rate is expected
to increase with increasing temperature.
• The application of heat normally increases the rate
of chemical reaction . every 10°c increase in
temperature normally increase the rate of reaction
2 to 3 times .
34. The activation energy
• As a reaction proceeds from reactants to
products, the system must pass through a state
whose energy is greater than that of the initial
reactants.
• This “barrier” is what prevents the reactants from
immediately becoming products.
• The activation energy, Ea, is a measure of this
barrier.
35. • The effect of temperature on reaction rate is
given by the Arrhenius equation:
K = is the specific reaction rate,
A = is a constant known as the Arrhenius factor or
the frequency factor,
Ea = is the energy of activation,
R = is the gas constant, 1.987 calories/deg mole,
T = is the absolute temperature.
36. • Plotting 1/T against log k. As seen in
equation:
• the slope = -Ea/2.303 R.
• the intercept on
the vertical axis
is log A.
slope = -Ea/2.303 R
log A
38. Accelerated Stability Testing
• Accelerated stability studies are designed to
increase the rate of chemical degradation or
physical change of a drug substance or drug
product by using exaggerated storage conditions
as part of the formal stability studies.
• Data from these studies, in addition to long-
term stability studies, can be used to assess
longer-term chemical effects at non accelerated
conditions
39. • the k values for the decomposition of a drug in
solution at various elevated temperatures are
obtained by plotting some function of
concentration against time,
• The logarithms of the specific rates of
decomposition are then plotted against the
reciprocals of the absolute temperatures
• the resulting line is extrapolated to room
temperature. The k25 is used to obtain a
measure of the stability of the drug under
ordinary shelf conditions.
40.
41.
42. • Expiration Dating
• The initial concentration of a drug decomposing
according to first-order kinetics is 94 units/mL.
The specific decomposition rate, k, obtained from an
Arrhenius plot is 2.09 × 10-5 hr-1 at room temperature,
25°C. Previous experimentation has shown that when
the concentration of the drug falls below 45 units/mL it is
not sufficiently potent for use and should be removed
from the market. What expiration date should be
assigned to this product?
43. • Log Ct = Log C0 – Kt/ 2.303
• K = 2.203/t X Log C0 / Ct
Log 45 units/mL= Log 94 units/mL - 2.09 × 10-5 hr-1 t
t = 3.5x104 hr = 4 years
2.203
1year x 365 day x 24hr = 8760 hr